Comprehensive Landscape of Heparin Therapy for COVID-19

Area of Science:

• Pharmacology
• Virology
• Immunology

Background:

• COVID-19, caused by SARS-CoV-2, is a global health crisis.
• Heparin, an anticoagulant, may offer benefits beyond thrombosis prevention in COVID-19 patients.
• Clinical and in vitro studies suggest heparin interacts with SARS-CoV-2.

Purpose of the Study:

• To review the pharmacological mechanisms of heparin in COVID-19.
• To evaluate the effectiveness and safety of heparin therapy for SARS-CoV-2 infection.
• To discuss heparin's potential multiple-targeting effects.

Main Methods:

• Review of clinical observations and biochemical studies on heparin and SARS-CoV-2.
• Analysis of pharmacological data on heparin's anticoagulant, anti-inflammatory, and antiviral activities.
• Assessment of existing evidence on heparin's efficacy and safety in COVID-19 management.

Main Results:

• Heparin demonstrates strong binding to the SARS-CoV-2 Spike protein, inhibiting viral entry.
• Heparin exhibits anti-inflammatory properties relevant to COVID-19 pathogenesis.
• Evidence suggests heparin may have direct antiviral effects against SARS-CoV-2.
• Clinical observations indicate symptom attenuation with heparin use.

Conclusions:

• Heparin presents a potential multi-targeting therapeutic agent for COVID-19.
• Heparin's anticoagulant, anti-inflammatory, and direct antiviral actions warrant consideration.
• Careful evaluation of heparin's benefits versus risks is crucial for its application in COVID-19 therapy.